Article

Robotic radical prostatectomy patients may have lower PSA recurrence

An international study analyzing data from almost 30,000 men treated with radical prostatectomy as monotherapy for high-risk prostate cancer provides some evidence that short- to medium-term oncologic outcomes are better for men who undergo robot-assisted laparoscopic RP (RALP) compared with open RP (ORP) and laparoscopic RP (LRP).

Washington-An international study analyzing data from almost 30,000 men treated with radical prostatectomy as monotherapy for high-risk prostate cancer provides some evidence that short- to medium-term oncologic outcomes are better for men who undergo robot-assisted laparoscopic RP (RALP) compared with open RP (ORP) and laparoscopic RP (LRP).

Related Videos
John P. Mulhall, MD, answers a question during a Zoom video interview
Hailey Frye answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Medcast series
1 expert in this video
Neeraja Tillu, MD, answers a question during a Zoom video interview
Related Content
Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
March 19th 2025

Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

Hannah Clarke
"The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Tiopronin delayed-release tablets available in US for patients with cystinuria
March 18th 2025

Tiopronin delayed-release tablets available in US for patients with cystinuria

Hannah Clarke
This announcement follows the successful launch of generic tiopronin delayed-release tablets last year.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
AHN Becomes the First Health System in Western Pennsylvania to Offer AI-Powered Therapy to Treat Enlarged Prostate
March 17th 2025

AHN Becomes the First Health System in Western Pennsylvania to Offer AI-Powered Therapy to Treat Enlarged Prostate

Allegheny Health Network
“We are incredibly proud to lead the way in Western Pennsylvania by introducing Aquablation therapy to patients in our region who are experiencing advanced stage BPH,” says Goutham Vemana, MD.
Exercise may improve erectile function in men with prostate cancer
March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke
“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.
© 2025 MJH Life Sciences

All rights reserved.